William Blair Issues Positive Outlook for Korro Bio Earnings

Korro Bio, Inc. (NASDAQ:KRRO) – Investment analysts at William Blair increased their Q3 2025 earnings estimates for shares of Korro Bio in a note issued to investors on Tuesday, August 12th. William Blair analyst M. Minter now expects that the company will post earnings per share of ($2.97) for the quarter, up from their previous forecast of ($3.03). The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. William Blair also issued estimates for Korro Bio’s Q4 2025 earnings at ($3.00) EPS, FY2025 earnings at ($11.21) EPS, Q1 2026 earnings at ($3.06) EPS, Q2 2026 earnings at ($3.09) EPS, Q3 2026 earnings at ($3.12) EPS, Q4 2026 earnings at ($3.14) EPS, FY2026 earnings at ($12.40) EPS, FY2027 earnings at ($13.19) EPS and FY2028 earnings at ($12.55) EPS.

KRRO has been the topic of a number of other reports. Chardan Capital reiterated a “buy” rating and issued a $25.00 price target on shares of Korro Bio in a report on Wednesday. HC Wainwright reduced their price target on shares of Korro Bio from $100.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday. Cantor Fitzgerald upgraded shares of Korro Bio to a “strong-buy” rating in a report on Tuesday, April 29th. Oppenheimer reduced their price target on shares of Korro Bio from $155.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, May 13th. Finally, Raymond James Financial reduced their price target on shares of Korro Bio from $153.00 to $147.00 and set a “strong-buy” rating on the stock in a report on Wednesday. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $86.83.

Korro Bio Stock Performance

Shares of NASDAQ KRRO opened at $20.26 on Friday. The company has a market cap of $190.24 million, a P/E ratio of -2.08 and a beta of 2.51. The firm’s fifty day moving average is $14.32 and its two-hundred day moving average is $18.12. Korro Bio has a 52-week low of $10.29 and a 52-week high of $98.00.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($2.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.54) by ($0.20). The business had revenue of $1.46 million for the quarter, compared to the consensus estimate of $0.41 million.

Hedge Funds Weigh In On Korro Bio

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Quarry LP purchased a new position in shares of Korro Bio during the 1st quarter worth about $35,000. Wells Fargo & Company MN boosted its stake in shares of Korro Bio by 32.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,392 shares of the company’s stock worth $129,000 after purchasing an additional 831 shares during the period. Deutsche Bank AG boosted its stake in shares of Korro Bio by 29.4% during the 4th quarter. Deutsche Bank AG now owns 4,110 shares of the company’s stock worth $156,000 after purchasing an additional 935 shares during the period. AlphaQuest LLC boosted its stake in shares of Korro Bio by 320.1% during the 1st quarter. AlphaQuest LLC now owns 9,196 shares of the company’s stock worth $160,000 after purchasing an additional 7,007 shares during the period. Finally, Legal & General Group Plc boosted its stake in shares of Korro Bio by 664.1% during the 4th quarter. Legal & General Group Plc now owns 4,325 shares of the company’s stock worth $165,000 after purchasing an additional 3,759 shares during the period. 13.18% of the stock is owned by hedge funds and other institutional investors.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).